下一代癌症診斷市場規模、佔有率和成長分析：按技術、應用、癌症類型、功能和地區 - 行業預測，2024-2031

2022年全球下一代癌症診斷市場規模將為116億美元，預測期（2024-2031年）複合年成長率為17.8%，從2023年的136.6億美元成長到2031年的430.2億美元。

由於從傳統實驗室測試向快速就地檢驗的轉變，下一代癌症診斷市場將顯著成長。先進診斷設備、套件和試劑的商業化預計將促進這一轉變。市場將受益於伴同性診斷的開拓，以增強個人化基因組醫學。根據2021年全球癌症觀察，2020年非何傑金氏淋巴瘤病例超過544,000例，何傑金氏淋巴瘤病例超過83,000例，白血病病例超過474,000例，多發性骨髓瘤病例數為176,000例。癌症是世界第二大死因，每年奪走約960萬人的生命，因此迫切需要開發更有效的診斷工具。新的癌症生物標記和測試的持續開拓進一步推動了市場擴張，這些生物標記和測試能夠實現更早、更準確的疾病檢測。每年報告的新病例超過 375,000 例，死亡率超過 44%，為了應對日益成長的癌症發病率和高死亡率，研究人員正在開發一種創新的微創診斷方法。

目錄

介紹

• 研究目的
• 定義
• 市場範圍

調查方法

• 資訊採購
• 次要/一級資訊來源
• 市場規模預測
• 市場假設與限制

執行摘要

• 市場概況展望
• 供需趨勢分析
• 按細分市場的機會分析

市場動態及展望

• 市場動態
  • 促進因素
  • 機會
  • 抑制因素
  • 任務
• 波特的分析

主要市場考察

• 市場成功的關鍵因素
• 競爭程度
• 關鍵投資機會
• 市場魅力指數
• 生態系繪圖
• 技術分析
• 供應鏈分析
• 價值鏈分析
• 管道分析

下一代癌症診斷市場：依技術分類

• 市場概況
• 次世代定序
• qPCR/多重檢測
• 實驗室晶片(LOAC)/RT-PCR
• 蛋白質微陣列
• DNA微陣列

下一代癌症診斷市場：按應用分類

• 市場概況
• 生物標記開發
• CTC分析
• 蛋白質體分析
• 表觀遺傳分析
• 遺傳分析

下一代癌症診斷市場：按癌症類型分類

• 市場概況
• 肺
• 胸部
• 冒號
• 脖子
• 其他

下一代癌症診斷市場：依功能分類

• 市場概況
• 治療監測
• 伴同性診斷
• 預言
• 癌症篩檢
• 風險分析

下一代癌症診斷市場規模：按地區

• 市場概況
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 義大利
  • 西班牙
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲 (MEA)
  • 海灣合作理事會國家
  • 南非
  • 其他中東/非洲地區

競爭格局

• 前5名企業對比
• 2023年主要企業市場定位
• 主要市場參與者所採取的策略
• 近期市集活動
• 主要企業市場佔有率(%)，2023年

主要企業簡介

• Abbott Laboratories（US）
• Agilent Technologies, Inc.（US）
• Bio-Rad Laboratories, Inc.（US）
• Danaher Corporation（US）
• Exact Sciences Corporation（US）
• F. Hoffmann-La Roche Ltd.（Switzerland）
• GE Healthcare（US）
• Guardant Health, Inc.（US）
• Hologic, Inc.（US）
• Illumina, Inc.（US）
• Merck & Co., Inc.（US）
• Myriad Genetics, Inc.（US）
• NanoString Technologies, Inc.（US）
• Natera, Inc.（US）
• NeoGenomics, Inc.（US）
• Qiagen NV（Netherlands）
• Quest Diagnostics Incorporated（US）
• Siemens Healthineers AG（Germany）
• Sysmex Corporation（Japan）
• Thermo Fisher Scientific, Inc.（US）
• Veracyte, Inc.（US）

Global Next Generation Cancer Diagnostics Market size was valued at USD 11.60 Billion in 2022 and is poised to grow from USD 13.66 Billion in 2023 to USD 43.02 Billion by 2031, at a CAGR of 17.8% during the forecast period (2024-2031).

The Next Generation Cancer Diagnostics Market is set for substantial growth driven by the shift from traditional laboratory testing to rapid point-of-care testing. This transition is expected to be bolstered by the commercialization of advanced diagnostic devices, kits, and reagents. The market will benefit from the development of companion diagnostics, which enhance personalized genomic medicine. According to the Global Cancer Observatory 2021, there were over 544,000 cases of non-Hodgkin lymphoma and 83,000 cases of Hodgkin lymphoma in 2020, along with 474,000 cases of leukemia and 176,000 instances of multiple myeloma. With cancer being the second leading cause of death worldwide, resulting in approximately 9.6 million deaths annually, there is an urgent need for more effective diagnostic tools. The market's expansion is further driven by the continuous development of new cancer biomarkers and tests, enabling earlier and more accurate disease detection. Researchers are focused on creating innovative, minimally invasive diagnostic methods to address the increasing incidence and high mortality rate of cancer, with over 375,000 new cases reported each year and a mortality rate exceeding 44%.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Next Generation Cancer Diagnostics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Next Generation Cancer Diagnostics Market Segmental Analysis

Global Next Generation Cancer Diagnostics Market is segmented on the basis of technology, application, cancer type, function, and region. By technology, the market is segmented into next-generation sequencing, qPCR & multiplexing, lab-on-a-chip (LOAC) & RT-PCR, protein microarrays, and DNA microarrays. By application, the market is segmented into biomarker development, CTC analysis, proteomic analysis, epigenetic analysis, and genetic analysis. By cancer type, the market is segmented into lung, breast, colorectal, cervical, and others. By function, the market is segmented into therapeutic monitoring, companion diagnostics, prognostics, cancer screening, and risk analysis. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East & Africa, and Latin America.

Drivers of the Global Next Generation Cancer Diagnostics Market

The growing demand for personalized medicine is significantly driving the next generation cancer diagnostics market. Personalized medicine focuses on tailoring treatments based on individual genetic profiles and other unique characteristics, and advanced diagnostic tools are essential for identifying patients who will benefit most from these customized therapies. Additionally, increasing awareness about the importance of early cancer detection is further fueling market growth. Early detection improves treatment outcomes and survival rates, and next generation diagnostic tools are pivotal in facilitating early cancer detection and enhancing screening programs.

Restraints in the Global Next Generation Cancer Diagnostics Market

Reimbursement issues pose a significant restraint on the Next Generation Cancer Diagnostics Market due to the current lack of clear and standardized reimbursement policies. The slow development of these policies complicates the adoption and utilization of advanced diagnostic technologies, as both healthcare providers and patients struggle to justify the associated costs. Discrepancies in reimbursement policies across different countries, regions, and healthcare systems, coupled with ongoing policy development and a lack of consensus, further hinder the market's growth and adoption.

Market Trends of the Global Next Generation Cancer Diagnostics Market

In the Next Generation Cancer Diagnostics Market, liquid biopsy tests are gaining traction as a groundbreaking alternative to traditional tissue biopsies. These tests, which analyze blood, urine, or other bodily fluids to detect cancer cells and biomarkers, offer a less invasive and more cost-effective method for cancer diagnosis and monitoring. The enhanced frequency and accuracy of results provided by liquid biopsies have spurred increased adoption, with numerous companies actively investing in their development and integration into clinical practice.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors of The Market
• Degree Of Competition
• Top Investment Pockets
• Market Attractive Index
• Ecosystem Mapping
• Technology Analysis
• Supply Chain Analysis
• Value Chain Analysis
• Pipeline Analysis

Global Next Generation Cancer Diagnostics Market by Technology

• Market Overview
• Next-generation Sequencing
• qPCR & Multiplexing
• Lab-on-a-chip (LOAC) & RT-PCR
• Protein Microarrays
• DNA Microarrays

Global Next Generation Cancer Diagnostics Market by Application

• Market Overview
• Biomarker Development
• CTC Analysis
• Proteomic Analysis
• Epigenetic Analysis
• Genetic Analysis

Global Next Generation Cancer Diagnostics Market By Cancer Type

• Market Overview
• Lung
• Breast
• Colorectal
• Cervical
• Others

Global Next Generation Cancer Diagnostics Market By Function

• Market Overview
• Therapeutic Monitoring
• Companion Diagnostics
• Prognostics
• Cancer Screening
• Risk Analysis

Global Next Generation Cancer Diagnostics Market Size By Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Abbott Laboratories (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agilent Technologies, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exact Sciences Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GE Healthcare (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Guardant Health, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hologic, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Illumina, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Myriad Genetics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NanoString Technologies, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Natera, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NeoGenomics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Qiagen N.V. (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Quest Diagnostics Incorporated (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sysmex Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Veracyte, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments